Table 2

Distribution of diagnoses in the anti-SSA and/or anti-SSB positive population according to the fine reactivity defined by immunodiffusion

nSLE % (95% CI)CLE % (95% CI)SCl % (95% CI)RA % (95% CI)PM/DM % (95% CI)pSS % (95% CI)Other % (95% CI)
CLE, cutaneous lupus without systemic involvement; ID, immunodiffusion; LIA, line immunoassay; PM/DM, polymyositis/dermatomyositis; pSS, primary Sjögren's syndrome; RA, rheumatoid arthritis; SCl, scleroderma; SLE, systemic lupus erythematosus.
SSA+ and/or SSB+18145.37.78.87.72.214.413.8
ID SSA+ and IDSSB+2766.7 (46.0 to 83.5)3.7 (0.1 to 19.0)3.7 (0.1 to 19.0)7.4 (0.9 to 24.3)018.5 (6.3 to 38.1)0
ID SSA+ and ID SSB−7061.4 (49.0 to 72.8)5.7 (1.6 to 14.0)04.3 (0.9 to 12.0)015.7 (8.1 to 26.4)12.9 (6.1 to 23.0)
ID SSA− and ID SSB+2114.3 (3.0 to 36.3)23.8 (8.2 to 47.2)014.3 (3.0 to 36.3)033.3 (14.6 to 57.0)14.3 (3.0 to 36.3)
ID SSA− and ID SSB−6328.6 (17.9 to 41.3)6.3 (1.8 to 15.5)23.8 (14.0 to 36.2)9.5 (3.6 to 19.6)6.3 (1.8 to 15.5)4.8 (1.0 to 13.3)20.6 (11.5 to 32.7)
LIA+